title: Papillomavirus, p53 alteration, and primary carcinoma of the vulva.
abstract: Twenty-nine samples from 28 cases of vulvar squamous cell carcinoma, of which 13 fulfilled the criteria of the bowenoid subtype (mean age 45 years, range 31-68) and 16 of the usual subtype of invasive squamous cell carcinoma (ISCC) (mean age 67.5 years, range 34-83) were investigated for human papillomavirus (HPV) DNA, TP53 alterations, and mdm2 and bcl-2 gene product deregulation. Microscopically all the bowenoid subtype cases (group I) showed a high-grade intraepithelial (VIN 3, carcinoma in situ) lesion associated with early invasive carcinoma in six cases and overt invasive carcinoma in one. By contrast, no evidence of early carcinoma was present in the ISCCs (group II). By in situ hybridization and/or Southern blot hybridization or polymerase chain reaction (PCR), HPV DNA was detected in all cases of group I and in four of 16 cases (25%) of group II, two only by Southern blot after PCR. By single-strand conformation polymorphism and immunocytochemistry only wild-type TP53 and absence of detectable p53 product, respectively, were found in all cases of group I, i.e., in high-risk HPV-positive carcinomas, whereas mutations and/or p53 overexpression accounted for 75% in group II, i.e., in mainly HPV-negative carcinomas. The TP53 gene mutations observed in invasive carcinomas were significantly related to node-positive cases (p = 0.04). Taken together and in agreement with in vitro data, these results support the view that an alteration of TP53, gained either by interaction with viral oncoproteins or by somatic mutations, is a crucial event in the pathogenesis of vulvar carcinomas, but that TP53 mutations are mainly associated with disease progression. Finally, a preliminary immunocytochemical analysis seems to speak against the possible involvement of both MDM2 and BCL-2 gene products in the development of vulvar carcinoma.
authors.affiliation: Division of Anatomical Pathology and Cytology, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Pilotti
authors.forename: L
authors.initials: L
authors.lastname: D'Amato
authors.forename: G
authors.initials: G
authors.lastname: Della Torre
authors.forename: R
authors.initials: R
authors.lastname: Donghi
authors.forename: A
authors.initials: A
authors.lastname: Longoni
authors.forename: M
authors.initials: M
authors.lastname: Giarola
authors.forename: G
authors.initials: G
authors.lastname: Sampietro
authors.forename: G
authors.initials: G
authors.lastname: De Palo
authors.forename: M A
authors.initials: MA
authors.lastname: Pierotti
authors.forename: F
authors.initials: F
authors.lastname: Rilke
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000209:etiology* / Q000473:pathology / Q000556:secondary; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000032:analysis; D009367:Neoplasm Staging; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications* / Q000473:pathology; D017354:Point Mutation; D018807:Polymorphism, Single-Stranded Conformational; D011518:Proto-Oncogene Proteins / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D014412:Tumor Virus Infections / Q000150:complications* / Q000473:pathology; D014846:Vulvar Neoplasms / Q000737:chemistry / Q000209:etiology* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000737:chemistry / Q000209:etiology* / Q000473:pathology
chemical_list: D004279:DNA, Viral; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53